Abstract
Primary and metastatic liver cancers are increasing in incidence, and the approaches with the longest survival are resection and transplantation. Posthepatectomy liver failure (PHLF) is the leading cause of mortality following liver resection. PHLF is largely due to liver insufficiency due to the insufficient size of the future liver remnant (FLR). In this review, we will describe portal vein embolization, which is a neoadjuvant therapy used to induce hypertrophy in the FLR before resection.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
